Senegal
Tuberculosis profile
Population  2013 14 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.9 (1.6–4.2) 21 (12–29)
Mortality (HIV+TB only) 0.42 (0.31–0.55) 3 (2.2–3.9)
Prevalence  (includes HIV+TB) 29 (15–46) 202 (106–328)
Incidence  (includes HIV+TB) 19 (17–22) 136 (121–153)
Incidence (HIV+TB only) 1.7 (1.5–1.9) 12 (10–13)
Case detection, all forms (%) 68 (61–77)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.1 (0.7–4.9) 17 (7–31)
MDR-TB cases among notified pulmonary
TB cases
230 (77–540) 150 (65–290)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 9 056   596
Pulmonary, clinically diagnosed 1 916   0
Extrapulmonary 1 618   0
       
Total new and relapse 13 186    
Previously treated, excluding relapses 329    
Total cases notified 13 515    
Among 13 515 new cases:
641 (5%) cases aged under 15 years;
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 214 (2%) 321 (35%) 674
Laboratory-confirmed RR-/MDR-TB cases     680
Patients started on MDR-TB treatment     48
TB/HIV 2013 Number (%)
TB patients with known HIV status 10 995 (81)
HIV-positive TB patients 907 (8)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 853 (94)
HIV-positive TB patients on antiretroviral therapy (ART) 631 (70)
HIV-positive people screened for TB 5 926  
HIV-positive people provided with IPT 131  
Treatment success rate (%)
New and relapse cases registered in 2012 84
Previously treated cases, excluding relapse, registered in 2012 69
HIV-positive TB cases, all types, registered in 2012 70
RR-/MDR-TB cases started on second-line treatment in 2011 70
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 6
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 3.7
% Funded domestically 37%
% Funded internationally 63%
% Unfunded <1%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-02 Data: www.who.int/tb/data